Maxcyte profit margin MXCT

Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.

Net margin, 12 months: n/m; not a meaningful number
Peer median: 10.6%

Maxcyte's net margin works out at −115% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal year	Net margin	Operating margin	Gross margin
FY2025	n/a	n/a	81.2%
FY2024	n/a	n/a	81.6%
FY2023	−91.8%	n/a	88.5%
FY2022	−53.3%	−61.8%	88.5%
FY2021	−56.3%	−53.7%	89.2%
FY2020	−45.2%	−42.3%	89.4%

Quarter by quarter

Quarter	Ended	Net margin, 12 months	Change on a year
Q2 FY26	Jun 30, 2026	n/a	n/a
Q1 FY26	Mar 31, 2026	n/a	n/a
Q4 FY25	Dec 31, 2025	n/a	n/a
Q3 FY25	Sep 30, 2025	n/a	n/a
Q2 FY25	Jun 30, 2025	n/a	n/a
Q1 FY25	Mar 31, 2025	n/a	n/a
Q4 FY24	Dec 31, 2024	n/a	n/a
Q3 FY24	Sep 30, 2024	−78.4%	+20.1 pts
Q2 FY24	Jun 30, 2024	−78.0%	+2.2 pts
Q1 FY24	Mar 31, 2024	−83.0%	−9.3 pts
Q4 FY23	Dec 31, 2023	−91.8%	−38.6 pts
Q3 FY23	Sep 30, 2023	−98.4%	−42.2 pts

Against its peers

Companies in Healthcare nearest Maxcyte's size, closest first, today.

Company	Profit margin
MXCTMaxcyte	n/m
PDEXPro DEX	17.6%
PLXProtalix BioTherapeutics	23.5%
NATRNatures Sunshine Products	3.7%
KEQUKewaunee Scientific	3.0%
ELMDElectromed	15.3%
ICCCImmucell	2.6%
UTMDUtah Medical Products	29.0%
INFUInfuSystem	6.0%
LFVNLifevantage	2.8%
SPROSpero Therapeutics	15.7%
Peer median	10.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Maxcyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.